Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Investigational New Drugs|September 25, 2021
Relapsing polychondritis after treatment with PD-1 blockadeTatsuya Ogimoto, Hironori Yoshida, Masanobu Mizuta, et al.
Internal Medicine (Tokyo, Japan)|April 29, 2026
A Case of Immunoglobulin A Vasculitis Induced by EthambutolKazuhiko Nakagawa, Takuma Ikeda, Yuki Yoshida, et al.
Respiratory Medicine Case Reports|June 15, 2019
Pembrolizumab-associated bronchiolitis in an elderly lung cancer patient required the treatment with an inhaled corticosteroid, erythromycin and bronchodilatorsTakafumi Yamaya, Hwang Moon Hee, Takayuki Aoyagi, et al.
BMC Cancer|March 4, 2025
Safety and efficacy of pemetrexed for patients with non-small cell lung cancer in the setting of renal impairment: a retrospective studyYusuke Shima, Hironori Yoshida, Keiichiro Suminaga, et al.
Oncology Letters|October 24, 2022
Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case seriesKentaro Hashimoto, Hiroaki Ozasa, Akihiko Yoshizawa, et al.
Molecular and Clinical Oncology|July 28, 2025
Durvalumab consolidation after chemoradiotherapy for locoregional recurrent non-small cell lung cancerKeiichiro Suminaga, Hironori Yoshida, Yusuke Shima, et al.
Cancer Science|October 26, 2022
Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancerMasatoshi Yamazoe, Hiroaki Ozasa, Takahiro Tsuji, et al.
Oncology Letters|August 7, 2023
CD47 polymorphism for predicting nivolumab benefit in patients with advanced non‑small‑cell lung cancerTatsuya Ogimoto, Hiroaki Ozasa, Hironori Yoshida, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 2021
PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockadeHironori Yoshida, Takashi Nomizo, Hiroaki Ozasa, et al.
Molecular Cancer Therapeutics|December 5, 2023
Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation-positive Lung CancerTatsuya Ogimoto, Hiroaki Ozasa, Takahiro Tsuji, et al.
Pageof 2